Comparative Pharmacology
Head-to-head clinical analysis: HYDROMOX R versus VISKAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROMOX R versus VISKAZIDE.
HYDROMOX R vs VISKAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide-like diuretic that inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
Viskazide is a combination of pindolol (a non-cardioselective beta-blocker with intrinsic sympathomimetic activity) and hydrochlorothiazide (a thiazide diuretic). Pindolol competitively blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule, decreasing sodium and water reabsorption, leading to reduced plasma volume and blood pressure.
Oral, 50 mg once daily, increased to 100 mg once daily if needed.
Oral: 1 tablet (pindolol 10 mg / hydrochlorothiazide 25 mg) once daily; may increase to 2 tablets once daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is 10-12 hours for the hydrochlorothiazide component and 4-6 hours for pindolol; clinical context: steady-state achieved in 2-3 days for pindolol and 3-5 days for hydrochlorothiazide.
Renal: approximately 70% as unchanged drug; biliary/fecal: approximately 30% as unchanged drug and metabolites.
Renal elimination (approximately 70% unchanged), with the remainder as inactive metabolites; biliary/fecal excretion is minor (<10%).
Category C
Category C
Thiazide Diuretic Combination
Beta Blocker/Thiazide Diuretic Combination